07:05:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOBX
SektorHälsovård
IndustriBioteknik
BerGenBio är ett norskt onkologibolag. Idag bedriver bolaget forskning och utveckling av hämmande läkemedel för behandling av aggressiva cancertyper. Bolaget har utvecklat ett flertal produkter vars sammansättning ämnar blockera proteinet AXL, ett protein positivt relaterat med spridning av cancercellerna. Bolaget grundades under 2007 och har sitt huvudkontor i Bergen.

Kalender

2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-22 Ordinarie utdelning BGBIO 0.00 NOK
2021-03-19 Årsstämma 2021
2021-02-10 Bokslutskommuniké 2020
2020-12-09 Extra Bolagsstämma 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-19 Kvartalsrapport 2020-Q1
2020-03-17 Ordinarie utdelning BGBIO 0.00 NOK
2020-03-16 Årsstämma 2020
2020-02-11 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-19 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-14 Ordinarie utdelning BGBIO 0.00 NOK
2019-03-13 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Ordinarie utdelning BGBIO 0.00 NOK
2018-05-14 Årsstämma 2018
2018-03-09 Extra Bolagsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning BGBIO 0.00 NOK
2017-03-22 Årsstämma 2017
2016-06-22 Ordinarie utdelning BGBIO 0.00 NOK
2016-06-21 Årsstämma 2016
2015-06-23 Ordinarie utdelning BGBIO 0.00 NOK
2015-06-22 Årsstämma 2015
2020-11-30 09:20:43
Bergen, Norway, 30 November 2020 - BerGenBio ASA (OSE:BGBIO), a
clinical-stage<br />
biopharmaceutical company developing novel, selective AXL kinase inhibitors
for<br />
severe unmet medical need, is pleased to announce it has been accepted for a<br
/>
poster presentation at the 62[nd]  Annual American Society of Hematology
(ASH)<br />
Meeting, being held virtually from 5-8 December 2020.<br />
<br />
The poster will provide an update from the Company's Phase II study of<br />
bemcentinib (BGBC003) in combination with low dose cytarabine (LDAC) in
elderly<br />
relapsed AML patients, and the Phase II BERGAMO trial in patients with
high-risk<br />
MDS or AML.<br />
<br />
Abstracts have been announced online, and details of the presentation are
below.<br />
<br />
Title: The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine
Is<br />
Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from
the<br />
Ongoing BGBC003 phase II Trial (NCT02488408)<br />
<br />
Date: Sunday, December 6, 2020<br />
<br />
Session name: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II<br />
<br />
Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)<br />
<br />
Link online to abstract<br />
here (https://ash.confex.com/ash/2020/webprogram/Paper136566.html)<br />
<br />
Title: Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic<br />
Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents<br />
<br />
Date: Saturday, December 5, 2020<br />
<br />
Session name: 637 Myelodysplastic Syndromes - Clinical Studies: Poster I<br />
Hematology Disease Topics & Pathways: Diseases, Therapies, MDS, Myeloid<br />
Malignancies, Clinically relevant<br />
<br />
Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)<br />
<br />
Link online to abstract<br />
here (https://ash.confex.com/ash/2020/webprogram/Paper140240.html)<br />
<br />
The poster will be available at www.bergenbio.com in the section:<br />
Investors/Presentations at the date of the ASH 2020 meeting.<br />
<br />
- End -<br />
<br />
About AML and the BGBC003 trial<br />
<br />
Acute myeloid leukaemia (AML) is a rapidly progressing blood cancer. AML is
the<br />
most common form of acute leukaemia in adults, where malignant AML blasts<br />
interfere with the normal functioning of the bone marrow leading to a
multitude<br />
of complications like anaemia, infections and bleeding. AML is diagnosed in
over<br />
20,000 patients in the US annually and is rapidly lethal if left untreated.<br
/>
Successful treatment typically requires intensive therapy or bone marrow<br />
transplantation, and relapse and resistance are common. Consequently, there
is<br />
an urgent need for effective novel therapies in relapsed/refractory patients,<br
/>
particularly those that are ineligible for intensive therapy or bone marrow<br
/>
transplant.<br />
<br />
The BGBC003 trial is a phase Ib/II multi-centre open label study of
bemcentinib<br />
in combination with cytarabine (part B2) and decitabine (part B3) in patients<br
/>
with AML who are unsuitable for intensive chemotherapy as a result of
advanced<br />
age or existing comorbidities. Up to 28 patients will be enrolled at centres
in<br />
the US, Norway, Germany and Italy.<br />
<br />
For more information please access trial NCT02488408 at
www.clinicaltrials.gov.<br />
<br />
About BerGenBio ASA<br />
<br />
BerGenBio is a clinical-stage biopharmaceutical company focused on developing<br
/>
transformative drugs targeting AXL as a potential cornerstone of therapy for<br
/>
aggressive diseases, including immune-evasive, therapy resistant cancers. The<br
/>
company's proprietary lead candidate, bemcentinib, is a potentially first-in<br
/>
-class selective AXL inhibitor in a broad phase II clinical development<br />
programme focused on combination and single agent therapy in lung cancer,<br />
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody,<br />
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio
is<br />
developing a companion diagnostic test to identify patient populations most<br
/>
likely to benefit from bemcentinib: this is expected to facilitate more<br />
efficient registration trials supporting a precision medicine-based<br />
commercialisation strategy.<br />
<br />
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The<br />
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more<br />
information, visit www.bergenbio.com<br />
<br />
Contacts<br />
<br />
Richard Godfrey CEO, BerGenBio ASA<br />
+47 917 86 304<br />
<br />
Rune Skeie, CFO, BerGenBio ASA<br />
rune.skeie@bergenbio.com<br />
+47 917 86 513<br />
<br />
International Media Relations<br />
<br />
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs<br />
<br />
Consilium Strategic Communications<br />
bergenbio@consilium-comms.com<br />
+44 20 3709 5700<br />
<br />
Media Relations in Norway<br />
<br />
Jan Petter Stiff, Crux Advisersstiff@crux.no<br />
+47 995 13 891<br />
<br />
Forward looking statements<br />
<br />
This announcement may contain forward-looking statements, which as such are
not<br />
historical facts, but are based upon various assumptions, many of which are<br
/>
based, in turn, upon further assumptions. These assumptions are inherently<br />
subject to significant known and unknown risks, uncertainties and other<br />
important factors. Such risks, uncertainties, contingencies and other
important<br />
factors could cause actual events to differ materially from the expectations<br
/>
expressed or implied in this announcement by such forward-looking statements.<br
/>
<br />
This information is subject to the disclosure requirements pursuant to section
5<br />
-12 of the Norwegian Securities Trading Act.